Objective To establish a multi-drug resistant model of temporal lobe epilepsy and observe the effect of hippocampal stimulation on pharmacoresistant epileptic rats and its possible mechanism with the use of indexes including after discharges (AD) of the amygdalae,the stimulus-induced seizures and the extracellular levels of γ-aminobutyrate (GABA).Methods Totally,120 Wistar rats were used for the amygdaloid kindled model of epilepsy by chronic stimulation of amygaloid basal lateral nucleus.Based on the successful kindled model of epilepsy,we selected the pharmacoresistant and pharmacosensitive epileptic rats according to their response to phenobabital and phenytoin.We then divided the pharmacoresistant epileptic rats into the hippocampal stimulation group and control group,with 8 rats in each group.Low-frequency stimulus was conducted for two weeks in the hippocampal stimulation group.The hippocampus extracellular fluid collected by microdialysis was then used to determine the levels of GABA by a high performance liquid chromatography method after hippocampal stimulation.Results The stimulus-induced seizures were inhibited significantly,and the frequency of the AD was decreased,as well as the amplitude,compared with the control group.The extracellular level of GABA in the 8:00-9:00 am and the 8:00-9:00 pm was (32.69 ± 7.80) and (35.76 ± 6.27) μg/ml,respectively,both significantly increased as compared with the control ((26.58 ± 6.87) μg/ml,t =-21.45,P =0.000 ; (31.50 ± 4.87) μg/ml,t =-15.74,P =0.000).Conclusions The low-frequency hippocampal stimulation inhibits the seizures of the kindled model of epilepsy and decreases the frequency,the amplitude,as well as the duration of the amygdale AD in the pharmacoresistant epileptic rats,which may be contributed to the increased GABA content in extracellular fluid of the brain after stimulation.

Objective:To evaluate the effectiveness of internal control of government procurement at public hospitals.Methods:Literature review and Delphi method were used to construct the internal control evaluation index system of government procurement at public hospitals, and the weight of the index system was determined by analytic hierarchy process. The index system was used to evaluate the internal control of government procurement in Hospital Z.Results:The evaluation index system of government procurement internal control of public hospitals covers all aspects of the whole process of government procurement, including 2 level-1 indexes of government procurement internal control unit level and government procurement internal control business level, 11 level-2 indexes and 27 level-3 indexes. The internal control of government procurement of Hospital Z was evaluated with an evaluation score of 81.37 points, an evaluation result relatively effective.Conclusions:The evaluation index system of government procurement internal control of public hospitals constructed in this study could quantitatively evaluate the effectiveness of each sector of government procurement internal control of public hospitals. It could meet the basic evaluation requirements of internal control of government procurement at public hospitals.

Objective:To investigate the efficacy and safety of TC (paclitaxel and carboplatin) regimen combined with bevacizumab in the treatment of advanced ovarian cancer.Methods:A prospective randomized controlled study was conducted. A total of 102 patients with advanced ovarian cancer admitted to Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University from January 2017 to April 2021 were selected and divided into the observation group and the control group according to random number table method, 51 cases in each group. The observation group was treated with TC regimen combined with bevacizumab, and the control group was treated with TC regimen. The clinical efficacy, carbohydrate antigen 125 (CA125) level, human epididymal protein 4 (HE4) level, thymidine kinase 1 (TK1) level, adverse reactions, the overall survival time, recurrence rate and mortality were compared between the 2 groups.Results:There were no statistically significant differences in baseline data such as age, tumor staging and tumor type between the observation group and the control group (all P > 0.05). The effective rate and the disease control rate of the observation group were 58.82% (30/51) and 88.24% (45/51), respectively, which were higher than those of the control group [37.25% (19/51) and 64.71 (33/51)], and the differences were statistically significant ( χ2 = 4.75, P = 0.029; χ2 = 7.85, P = 0.005). Before treatment, there were no statistically significant differences in CA125, HE4 and TK1 levels between the 2 groups (all P > 0.05). After treatment, CA125, HE4 and TK1 levels in the observation group were lower than those in the control group (all P < 0.05). There were no statistically significant differences in the incidence of myelosuppression, liver function damage, gastrointestinal reaction, proteinuria, diarrhea and abdominal pain, high blood pressure between the observation group and the control group (all P > 0.05). The 2-year overall survival rate of the observation group was higher than that of the control group (82.0% vs. 64.7%), while the recurrence rate of the observation group was lower than that of the control group [21.57% (11/51) vs. 45.10% (23/51)], and the differences were statistically significant (all P < 0.05). Conclusions:TC regimen combined with bevacizumab has favorable therapeutic effects and good safety in the treatment of advanced ovarian cancer, which is beneficial to prolong the survival time of patients.